Payload Information
General Information of This Payload
| Payload ID | PAY0OWPRN |
|||||
|---|---|---|---|---|---|---|
| Name | CC-885 |
|||||
| Synonyms |
CC-885
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C22H21ClN4O4 |
|||||
| Isosmiles | CC1=C(Cl)C=C(NC(NCC2=CC=C(C3=O)C(CN3C(C4=O)CCC(N4)=O)=C2)=O)C=C1 |
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C22H21ClN4O4/c1-12-2-4-15(9-17(12)23)25-22(31)24-10-13-3-5-16-14(8-13)11-27(21(16)30)18-6-7-19(28)26-20(18)29/h2-5,8-9,18H,6-7,10-11H2,1H3,(H2,24,25,31)(H,26,28,29)
|
|||||
| InChIKey |
DOEVCIHTTTYVCC-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
440.887 |
Polar area |
107.61 |
||
Complexity |
1061.441052 |
xlogp Value |
2.73112 |
|||
Heavy Count |
31 |
Rot Bonds |
4 |
|||
Hbond acc |
4 |
Hbond Donor |
3 |
|||
The activity data of This Payload
| Standard Type | Value | Units | Cell line | Disease Model | Cell line ID | Reference |
|---|---|---|---|---|---|---|
| Cellular activity | 15 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 19.3 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 3 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 3 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 3.9 | % |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Cellular activity | 4 | % | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.2 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.3 | nM |
PBMC cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.3 | nM |
MM1.S cells
|
Plasma cell myeloma, Multiple myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.3 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Effective Concentration (EC50) | 0.3 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.3 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM |
Z-138 cells
|
Mantle cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 0.4 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 0.8 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Degradation Concentration (DC50) | <1 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Effective Concentration (EC50) | <1 | nM |
MOLT-4 cells
|
Adult T acute lymphoblastic leukemia
|
||
| Half Maximal Effective Concentration (EC50) | <1 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Degradation Concentration (DC50) | <1 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Degradation Concentration (DC50) | <1 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 1 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 1.2 | nM |
JeKo-1 cells
|
Mantle cell lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 1.5 | nM |
THP-1 cells
|
Acute monoblastic/monocytic leukemia, Childhood acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 10 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
U-937 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 11 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 18 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
U-266 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 2 | nM |
NB-4 cells
|
Acute promyelocytic leukemia, Acute promyelocytic leukemia with PML-RARA
|
||
| Half Maximal Inhibitory Concentration (IC50) | 20.4 | nM |
Raji cells
|
EBV-related Burkitt lymphoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >20000 | nM |
WI-38 cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 21 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 3 | nM |
HL-60 cells
|
Acute myeloblastic leukemia with maturation, Adult acute myeloid leukemia with maturation
|
||
| Half Maximal Inhibitory Concentration (IC50) | 30 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Cytotoxic Concentration (CC50) | 440 | nM |
SNU-C4 cells
|
Colorectal carcinoma
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
MV4-11 cells
|
Childhood acute monocytic leukemia
|
||
| Half Maximal Effective Concentration (EC50) | <5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Effective Concentration (EC50) | 5 | nM |
Cancer cells
|
Multiple myeloma, Plasma cell myeloma
|
Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 5 | nM |
MCF-10A cells
|
Normal
|
||
| Half Maximal Inhibitory Concentration (IC50) | 5.5 | nM |
RPMI-8226 cells
|
Plasma cell myeloma
|
||
| Half Maximal Inhibitory Concentration (IC50) | >5000 | nM |
PBMC cells
|
Normal
|
||
| Half Maximal Effective Concentration (EC50) | 59 | nM | Undisclosed | Undisclosed | Undisclosed | |
| Half Maximal Inhibitory Concentration (IC50) | 7 | nM |
KG-1 cells
|
Adult acute myeloid leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 73 | nM |
OCI-AML-3 cells
|
Adult acute myelomonocytic leukemia, Acute myelomonocytic leukemia
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8 | nM |
MOLM-13 cells
|
Acute monoblastic/monocytic leukemia, Adult acute monocytic leukemia, Myelodysplastic syndrome
|
||
| Half Maximal Inhibitory Concentration (IC50) | 8 | nM |
KG-1a cells
|
Leukemia
|
Each Antibody-drug Conjugate Related to This Payload